Kymera Therapeutics Menu About Kymera Inventing New Possibilities, Transforming Treatment Paradigms Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development. The Kymera Team Management Team Nello Mainolfi, PhD Co-Founder, President and Chief Executive Officer Read Bio Elaine Caughey, MBA Chief Business Officer Read Bio Jared Gollob, MD Chief Medical Officer Read Bio Bruce Jacobs, CFA, MBA Chief Financial Officer Read Bio Karen Weisbach Vice President, People and Culture Read Bio Ashwin Gollerkeri, MD Senior Vice President, Head of Development Read Bio Juliet Williams, PhD Senior Vice President, Head of Biology Read Bio Brian Albarran, PhD, MBA Vice President, Strategy and Operations Read Bio Jolly Bhatia Vice President, Quality Read Bio Melissa Brody Vice President, Business Development Read Bio Jeff Davis, MBA Vice President, Head of Clinical Operations Read Bio Chris De Savi, PhD Vice President, Head of Drug Discovery Read Bio Kevin Dushney Vice President, Information Technology Read Bio William Leong, PhD Vice President of Chemistry, Manufacturing and Controls (CMC) Read Bio Karen Martin, JD, PhD Vice President, Head of Legal Read Bio Haojing Rong, PhD Vice President, Preclinical Development Read Bio Anthony Slavin, PhD Vice President, Immunology Read Bio Michael Todisco, MS Vice President, Accounting & Finance Read Bio Working at Kymera Alice McDonald | Length: 20 seconds Matt Weiss | Length: 23 seconds Kymera Therapeutics KYMERA THERAPEUTICS 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472 Careers Contact Us Terms of Service Privacy Policy

Kymera Therapeutics Menu Scientific Resources Select Resources Select Category Posters, Presentations & Publications 10/28/21 4th Annual TPD Summit, October 28, 2021 View Presentation 10/27/21 4th Annual TPD Summit, October 27, 2021 View Presentation 10/27/21 Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers View Presentation 10/26/21 4th Annual TPD Summit, October 26-29, 2021 View Presentation Kymera Therapeutics KYMERA THERAPEUTICS 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472 Careers Contact Us Terms of Service Privacy Policy